Gene therapy hope for babies with rare muscle disease
NCT ID NCT07070999
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study tests a single dose of GB221, a gene therapy that delivers a working SMN1 gene, in infants aged 2 weeks to under 12 months with spinal muscular atrophy (SMA) Type 1. The goal is to see if it is safe and helps improve motor function. The trial includes both symptomatic and presymptomatic babies, and will monitor side effects and developmental milestones.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GB221 (a gene therapy that delivers a working SMN1 gene)
- What this could lead to
- If it works, this could point toward a treatment that helps infants with SMA Type 1 gain motor skills and avoid permanent ventilation.
- What could go wrong
- This is an early phase 1-2 trial with only 22 participants, so results may not apply to everyone. There are risks of side effects like immune reactions or lab abnormalities.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY TYPE I are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Hospital de Clínicas de Porto Alegre
RECRUITINGPorto Alegre, Rio Grande do Sul, 90035-903, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.